NanoSomiX and Beckman Coulter Diagnostics collaborate on EV-enabled immunoassays for neurodegenerative diseases

NanoSomiX, Inc. has announced plans to collaborate with Beckman Coulter Diagnostics to explore the development of next-generation immunoassays for neurodegenerative diseases. The collaboration aims to address the need for sensitive, scalable blood tests capable of detecting low-abundance, brain-specific biomarkers associated with neurological conditions.

Focus on brain-derived extracellular vesicles

NanoSomiX’s proprietary platform centers on EVs derived from defined brain cell populations, including neurons and glial cells. By isolating and analyzing these brain-derived EVs from a small volume of blood, the company seeks to provide access to brain-relevant biomarkers that are otherwise difficult to measure non-invasively.

Advancing immunoassay development for neurodegenerative diseases

NanoSomiX has developed and published unique EV-based immunoassay platforms applicable to a wide spectrum of neurodegenerative diseases and neuro injury. These platforms are designed to support biomarker discovery and validation by enabling the measurement of brain cell–specific signals in blood.

The NanoSomiX platform is compatible with high-throughput testing systems, positioning it as a strong foundation for translational research and scalable immunoassay development. Through this planned collaboration, NanoSomiX and Beckman Coulter Diagnostics intend to explore how EV-enabled immunoassays could be integrated into automated workflows to support both research and potential clinical applications in neurology.

Supporting biomarker discovery across neurological conditions

NanoSomiX currently collaborates with academic and commercial partners on research involving neuron-, astrocyte-, and oligodendrocyte-derived EVs. These collaborations aim to advance biomarker discovery and validation across a broad range of neurological conditions, including neurodegenerative diseases and neuro injury.

By leveraging brain-derived EVs and high-throughput immunoassay platforms, NanoSomiX and its partners seek to improve the detection and monitoring of brain-specific biomarkers in blood, with the goal of supporting better understanding of disease mechanisms, tracking disease progression, and evaluating therapeutic response.

“EVs — particularly brain-derived EVs — offer a non-invasive way to access meaningful signals from the brain using a small volume of blood,” said NanoSomiX executive Dr. Dennis Van Epps, VP, Scientific Affairs.

“NanoSomiX has developed EV-based immunoassays that measure biomarkers from neuron- and other brain cell–derived EVs, supporting research into disease mechanisms, progression, and therapeutic response. We are excited to work with Beckman Coulter Diagnostics to help translate this scientific foundation toward scalable, automated immunoassay solutions for both research and clinical settings.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>